{
    "clinical_study": {
        "@rank": "2978", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "SYP-1018 200mg \u2192 Voriconazole 200mg"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Voriconazole 200mg \u2192 SYP-1018 200mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetic properties  and safety of\n      SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend)."
        }, 
        "brief_title": "Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend)", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Systemic Mycotic Infection", 
        "condition_browse": {
            "mesh_term": "Mycoses"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adults 20-45 years of age\n\n          -  Weight of \u2265 60kg \u2264 90kg with BMI of \u2265 19 and < 27 (BMI(kg/m2)=\n             weight(kg)/{height(m)}2\n\n          -  Voluntary written informed consent\n\n        Exclusion Criteria:\n\n          -  History or presence of significant renal, neurologic, pulmonary, endocrine,\n             hematology, oncology, urologic, cardiovascular, musculoskeletal or psychiatric\n             disease\n\n          -  Drug allergies to Voriconazole\n\n          -  Recent history or evidence of drug abuse\n\n          -  Recent participation(within 2 months) in other clinical studies\n\n          -  Recent donation of blood(within 2months), plasma(within 1month) or transfusion(within\n             1month)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657201", 
            "org_study_id": "SYP1018"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "description": "SYP-1018 200mg, Intravenous administration", 
                "intervention_name": "SYP-1018 200mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "description": "Voriconazole 200mg, Intravenous administration", 
                "intervention_name": "Voriconazole 200mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Voriconazole"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 20, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Clinical Research Institute, Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Two-Treatment, Two-Period, Two-Sequence, Cross-over Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend) in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "AUClast, Cmax", 
            "measure": "Pharmacokinetics parameters", 
            "safety_issue": "No", 
            "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657201"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUCinf, Tmax, T1/2, CL", 
                "measure": "Pharmacokinetics parameters", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24h"
            }, 
            {
                "description": "Adverse events, Laboratory assessments, Vital signs, Electrocardiograms(ECGs)", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "16 days"
            }
        ], 
        "source": "Samyang Biopharmaceuticals Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samyang Biopharmaceuticals Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}